Q2 2025 Highlights - Adjusted EPS was $016[20] - The Rule of 40 score was 94%[22] - Adjusted free cash flow was $569 million, with a 57% margin[22] - Adjusted operating income was $464 million, with a 46% margin[22] - The company closed 157 deals of at least $1 million, 66 deals of at least $5 million, and 42 deals of at least $10 million[22] Revenue Growth - Total revenue grew by 48% year-over-year (Y/Y) and 14% quarter-over-quarter (Q/Q) to $1004 billion[22] - Excluding Strategic Commercial Contracts, total revenue grew by 49% Y/Y and 14% Q/Q[22] - US revenue grew by 68% Y/Y and 17% Q/Q to $733 million[22] - US commercial revenue grew by 93% Y/Y and 20% Q/Q to $306 million[22] - US government revenue grew by 53% Y/Y and 14% Q/Q to $426 million[22] US Commercial Performance - US commercial remaining deal value (RDV) grew by 145% Y/Y and 20% Q/Q to $28 billion[22] - US commercial total contract value (TCV) reached a record high of $843 million, representing a 222% Y/Y increase[22] - US Commercial Customer Count grew 64% Y/Y[58] Financial Position - The company ended Q2 2025 with $60 billion in cash, cash equivalents, and US Treasury securities and no debt[90] Q3 and FY 2025 Outlook - For Q3 2025, the company expects revenue between $1083 billion and $1087 billion and adjusted income from operations between $493 million and $497 million[94] - For FY 2025, the company expects revenue between $4142 billion and $4150 billion, US commercial revenue in excess of $1302 billion (at least 85% growth), adjusted income from operations between $1912 billion and $1920 billion, and adjusted free cash flow between $18 billion and $20 billion[93]

Financial Performance - PRA Group achieved net income of $42 million in Q2 2025, or $13 million excluding the after-tax gain from the RCB sale in Brazil[24] - The company's revenues increased by 1% to $288 million in Q2 2025[25] - Adjusted EBITDA grew by 16% year-over-year[29] Portfolio and Investments - The company's purchase price multiples (PPMs) have improved, with 1H 2025 PPMs at 1.82x for Purchases and 2.14x for ERC[16] - Total cash collections increased by 13%[19] - Portfolio income is growing, with a 14% increase in Q1 2025 and a 20% increase in Q2 2025[22] Capital Structure and Strategy - PRA Group has no debt maturities until 2027[12] - The company repurchased $10 million of shares during the quarter[32, 34] - The company has $841 million available under its credit facilities as of June 30, 2025[34]

Financial Performance - Q2 2025 revenue reached $106 million[11] - The company reported an operating loss of $1.1 million[15] - Earnings per share stood at $0.22[19] - Revenue per active earning coach (AEC) was $4,630[13, 14] - As of June 30, 2025, cash and investments totaled $163 million[6, 21, 22] Coach Network and Productivity - The company has 22,800 active earning coaches[20] - Revenue per active earning coach declined 6.9% year-over-year but increased sequentially for the second consecutive quarter[8] - New coach productivity exceeded the same period last year[8] - 60% of coaches have had at least one client on GLP-1 medications[30, 70] Strategic Initiatives - The company is focusing on science-driven innovation and offer evolution[23, 65] - The Premier+ program streamlines pricing and processes to improve retention and aid recruitment[25, 48, 51] - The OPTAVIA EDGE program is designed to drive coach productivity, client acquisition, and leadership development[52, 71] Market and Health Focus - The company is addressing the rising metabolic health challenge, with 9 out of 10 U S adults being metabolically unhealthy[31, 69] - The OPTAVIA 5&1 Plan has been shown to impact key drivers of metabolic health, retaining 98% of lean mass in a clinical trial[38, 40] Q3 2025 Guidance - The company projects Q3 2025 revenue between $70 million and $90 million[75] - Q3 2025 loss/earnings per share is expected to be between ($0.60) and $0.00[75]

Investor Presentation Q2 2025 Update 1 Certain statements in this presentation may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Offerpad's future financial or operating performance. For example, statements regarding Offerpad's financial outlook, including homes sold, revenue and Adjusted EBITDA, for the first quarter of 2025, and expectations regarding market conditions, st ...

Company Overview - The company operates a leading online insurance marketplace, connecting consumers and insurance providers[10] - The company's platform leverages over 4 billion consumer data points[15,22] - The company has diversified distribution model with approximately 60 carriers and 6,000 third-party agents[15] Market Opportunity - The total P&C distribution and advertising spend market is estimated at $117 billion annually[10,17] - Digital advertising spend within the P&C insurance market is $7 billion[17] - The company estimates its share of the P&C distribution and advertising spend market is less than 1%[18] - The estimated digital advertising spend growth in the U S P&C insurance market is approximately 15% annually from 2023 to 2026[18] Financial Performance - The company's Q2 2025 revenue increased by 34% year-over-year to $156 6 million[32,43] - Auto insurance revenue in Q2 2025 grew by 36% year-over-year to $139 6 million[43] - Home/Renters insurance revenue in Q2 2025 increased by 23% year-over-year to $17 0 million[43] - Adjusted EBITDA for Q2 2025 was $22 0 million, representing a 70% increase year-over-year[32]

Financial Performance & Guidance - Q2 2025 total revenues reached $2.96 billion, compared to $2.65 billion in Q2 2024[48] - The company reiterated its 2025 total revenue guidance of $11.85-$12.0 billion[7] - Non-GAAP operating income for Q2 2025 was $1.33 billion, with a 45% operating margin[48] - Non-GAAP net income for Q2 2025 was $1.17 billion, or $4.52 per share diluted[48] - The company expects combined non-GAAP R&D, AIPR&D, and SG&A expenses to be $4.9-$5.0 billion for 2025[49] Key Product Updates - ALYFTREK generated $157 million in revenue in Q2 2025 and is approved for ages 6+ in the U S, U K, EU & Canada[33,48] - CASGEVY generated $30 million in revenue in Q2 2025, with 29 total patients infused since launch[40,48] - JOURNAVX generated $12 million in revenue in Q2 2025, with >110,000 prescriptions successfully filled as of mid-July[47,48] Pipeline Development - The company plans global regulatory submissions for Zimislecel (T1D) in 2026, targeting an initial launch to ~60,000 severe T1D patients[7,12] - Povetacicept (IgAN) Phase 3 interim analysis cohort is fully enrolled, with potential U S filing for accelerated approval in H1 2026[7,19] - VX-407 (ADPKD) Phase 2 proof-of-concept study is set to begin in Q3 2025, targeting up to ~30,000 patients with a subset of variants in the PKD1 gene[7,30]

Financial Performance & Revenue - Q2 2025 revenue breakdown: Projects contribute $358.1 million, Energy & incentive revenue from owned energy assets plus recurring O&M from projects is $90.9 million, and other sources including services, software and integrated PV account for $23.3 million[5] - Year-to-date 2025, total revenue is $825 million, with projects accounting for 74%, assets for 15%, O&M for 6%, and other sources for 5%[7] - Year-to-date 2025, adjusted EBITDA is $97 million, with assets contributing 66%, projects 26%, O&M 5%, and other sources 3%[7] - Ameresco's total debt is $1.82 billion, of which $1.50 billion is energy asset debt[14, 15] - Of the energy asset debt, $0.99 billion is associated with operating energy assets, and $0.51 billion is associated with energy assets in development & construction[16] Energy Assets & Backlog - Operating energy assets total 749 MWe, comprising 56% solar (421 MW), 22% battery (166 MW), 11% non-RNG biogas (83 MWe), 9% RNG biogas (70 MWe), and 1% other[10, 11] - Energy assets in development & construction total 615 MWe, with 40% battery, 23% firm generation, 22% solar, and 15% biogas[11] - The company has a diversified total project backlog of $5.1 billion as of June 30, 2025, with $2.4 billion in awarded project backlog and $2.7 billion in contracted project backlog[21, 23] - The operating energy assets have a $1.3 billion backlog with a 15.1 year weighted average PPA remaining, plus an additional estimated revenue from market price RNG of $1.45 billion[21] Sustainability Impact - Since 2010, Ameresco's renewable energy assets & customer projects delivered a carbon emission reduction equivalent to over 125 million metric tons of CO2[30]

Non-GAAP Financial Measures This presentation includes both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non- GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP R&D expenses and Non-GAAP SG&A expenses are defined by the company ...

SI-BONE Corporate Overview August 2025 Forward-Looking Statements This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the neg ...

Financial Performance - Revuforj net revenue in 2Q25 reached $28.6 million, representing a 43% quarter-over-quarter growth[6] - Niktimvo net revenue reported by Incyte in 2Q25 was $36.2 million, a substantial increase from $13.6 million in the first two months of Q1 launch[9] - Syndax reported $9.4 million in collaboration revenue from Niktimvo in 2Q25, achieving profitability in the first full quarter[9] - Syndax holds a strong financial position with $518 million in cash and equivalents as of June 30, 2025[28] Product Pipeline and Market Opportunity - Syndax estimates a $5B+ Total Addressable Market (TAM) for Revuforj and another $5B+ TAM for Niktimvo, indicating a $10B+ market opportunity across R/R and frontline indications[4, 30] - The initial Niktimvo indication represents a $2B U S market opportunity, with potential for label and geographic expansion leading to a $5B+ TAM[19, 20] - Approximately 33% of KMT2A patients are estimated to have proceeded to hematopoietic stem cell transplantation (HSCT) following Revuforj treatment[6, 12] Clinical Data and Development - Phase 2 Relapsed/Refractory (R/R) mNPM1 AML data for Revumenib showed a 26% (20/77) CR+CRh rate and a 48% (37/77) Overall Response Rate (ORR)[26] - Phase 1 R/R NUP98r AML data for Revumenib showed a 60% (3/5) ORR[26] - Over 80% of bone marrow transplant centers have ordered Niktimvo[18]